SGLT-2 inhibitors reduce dialysis risk: landmark study
Australian-led review finds the gliflozins reduce risk of death by 33%
SGLT-2 inhibitors reduce the risk of kidney dialysis, transplantation and death from kidney disease by one-third, a landmark Australian-led review has found.
The findings provide the strongest evidence yet that the drugs should be routinely offered to patients with type 2 diabetes at risk of progressive kidney disease, the researchers say.
